Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE-2494 in Healthy Postmenopausal Women
NCT03478319Phase 1Completed
- Start
- Feb 2018
- Primary completion
- Jun 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ACE-2494 in osteoporosis and Sarcopenia (6 cohorts). Primary endpoint: Number of participants with ACE-2494 treatment-related adverse events. Started Feb 2018; status: completed.
02
Drugs
ACE-2494
03
Conditions
osteoporosisSarcopenia
Beyond the preview
Go deeper on NCT03478319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03478319.